These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29763999)

  • 21. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
    Berndt-Zipfel C; Michelson G; Dworak M; Mitry M; Löffler A; Pfützner A; Forst T
    Cardiovasc Diabetol; 2013 Apr; 12():59. PubMed ID: 23565740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
    Ahrén B
    Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
    Deacon CF
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():34-46. PubMed ID: 29364584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into the older hypoglycemic agents in type 2 diabetes therapy.
    Cao M; Bloomgarden Z
    J Diabetes; 2020 Nov; 12(11):844-847. PubMed ID: 32767624
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
    Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N
    Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
    Fadini GP; Albiero M; Menegazzo L; de Kreutzenberg SV; Avogaro A
    Diabetes Obes Metab; 2012 Jun; 14(6):518-22. PubMed ID: 22171692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Contra].
    Müller UA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):547. PubMed ID: 21351042
    [No Abstract]   [Full Text] [Related]  

  • 34. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Chen YW; Wang JS; Sheu WH; Lin SY; Lee IT; Song YM; Fu CP; Lee CL
    PLoS One; 2017; 12(2):e0171753. PubMed ID: 28182722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
    Haidinger M; Werzowa J; Voigt HC; Pleiner J; Stemer G; Hecking M; Döller D; Hörl WH; Weichhart T; Säemann MD
    Trials; 2010 Oct; 11():91. PubMed ID: 20925938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
    Ristic S; Byiers S; Foley J; Holmes D
    Diabetes Obes Metab; 2005 Nov; 7(6):692-8. PubMed ID: 16219012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.